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For more than two decades, bupropion has been clinically prescribed for the
treatment of depression (Wellbutrin), and more recently for smoking cessa-
tion (Zyban). Bupropion is conventionally described as a dual norepinephrine
dopamine reuptake inhibitor, therefore effective as an antidepressant. However,
we and others have shown that it also interacts with receptors of the Cys-loop
superfamily, namely neuronal nicotinic acetylcholine receptors. In the contin-
uum of exploring the molecular interactions of bupropion with other prominent
members of the Cys-loop superfamily, we report here that bupropion addition-
ally inhibits 5-hydroxytryptamine (serotonin) type 3A receptors (5-HT3ARs).
5-HT3ARs are cation-conducting, homo-pentameric ligand-gated ion channels
of the Cys-loop superfamily which are structurally and functionally distinct
from other serotonin receptors that are G-proteins. 5-HT3 receptors are cur-
rent targets for anti-emetics mainly used in cancer chemotherapy, as well as
potential future targets for disorders including anxiety, schizophrenia, and
Alzheimer’s disease.
Here we characterized our newly-identified interaction of bupropion with 5-
HT3ARs with electrophysiological and radioligand binding studies. In oocytes,
bupropion inhibited 5-HT3AR-mediated currents with an IC50 value of 87 mM
(nH ¼ 1.2). That 300 mM bupropion inhibited [3H]-5-HT or [3H]-granisetron
(a competitive antagonist) binding by ~ 20% indicated at best weak interaction
with the agonist binding site. In contrast, the effect of different concentrations
of bupropion on serotonin concentration-response curves suggested a non-
competitive nature of interaction. Along these lines, importantly, the inhibition
of serotonin-evoked currents recorded from oocytes was proportional to the
length of preincubation time with bupropion.
In summary, our results are indicative of a negative allosteric interaction of
bupropion with the 5-HT3AR. Currently, experiments are underway to identify
the site(s) of interaction for bupropion within the 5- HT3AR.
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Pentameric ligand-gate ion channels (pLGIC) such as the GABAA-, 5-HT3-
and Glycine receptor play a crucial role in neurotransmission and are targeted
by a wide variety of drugs including anesthetics, benzodiazepines, and anticon-
vulsants. Despite their high pharmacological importance, little is known about
the pathway from neurotransmitter binding in the extracellular domain to the
opening of the channel in the transmembrane domain. Partly, this is due to
the lack of high-resolution structural data of pharmacologically relevant
receptors. Recently however, the crystallographic structures of the C. elagans
glutamate-gated chloride channel (GluCl) both in an apo- as well as in a pre-
sumed open state became available (PDB: 4TNV, 4TNW; 3RHW). Based on
theses structures along with observations made from molecular dynamics sim-
ulations, we focused our interest on one specific loop in the extracellular
domain. We have used electrophysiological experiments on Xenopus oocytes
to explore the effect of mutations in loop F on the activation of GluCl by
glutamate. We also investigated the influence of the partial allosteric agonist
ivermectin on glutamate response both in presence and absence of the same
mutations in loop F. We found that mutation of a residue in this region has a
significant influence on glutamate response. This suggests that this region plays
an important role in the pathway between ligand binding to channel opening.
These insights should help to better understand the underlying mechanism of
this receptor family and might open up new possibilities for drug treatment.
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Texas Tech University Health Sciences Center, Lubbock, TX, USA.Bupropion is one of the most common drugs prescribed for treating depression
and aiding smoking cessation, and is generally well tolerated with the exception
of a rare dose-dependent incidence of seizures. It inhibits norepinephrine
and dopamine reuptake, as well as noncompetitively antagonizes neuronal
nicotinic acetylcholine receptors, which are members of the Cys-loop super-
family. While investigating its effects on other key members of this superfam-
ily, bupropion showed complex modulation of the g-aminobutyric acid type A
(GABAA) a1b2g2 receptor function.
In the brain, GABAA a1b2g2 receptors are one of the most abundant chloride-
conducting hetero-pentameric ligand-gated ion channels. They are targets for a
number of drugs including anesthetics, anticonvulsants, anxiolytics, hypnotics,
and muscle relaxants.
To the best of our knowledge, the interaction of bupropion with the GABAA
receptor has not yet been described. Therefore, the primary goal of this study
was to characterize the functional interactions of bupropion with the GABAA
a1b2g2 receptor. In oocytes, bupropion-alone (0.1 mM - 3 mM) directly
activated GABAA receptor-mediated currents. The comparison of dose-
response curves showed that bupropion-activation was lower in potency
(EC50¼1.5 mM vs. 1.3 mM) and efficacy (49.5% vs. 100%) than that for
GABA, consistent with partial agonism of the GABAA receptor. Interestingly,
at lower concentrations (0.001 mM - 100 mM) bupropion inhibited 0.5 mM
GABA-induced currents by ~ 8 - 20%; in contrast, at higher concentrations
(1 mM - 3 mM) it potentiated GABA-induced currents by ~ 50 - 70%. Notably,
in many ways bupropion mimics the actions of some of the general anesthetics
(e.g. propofol) at the GABAA receptor. This warrants exploring the bupropion
binding site(s) within these receptors.
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GABA is the predominant mediator of inhibitory neurotransmission in the
brain, and upon release rapidly activates ionotropic GABAARs. These receptors
are members of the pentameric ligand gated ion channel (pLGIC) family and
are the targets of a range of clinical and endogenous allosteric modulators,
including general anesthetics, alcohols and neurosteroids. Many of these
compounds bind in the transmembrane domain (TMD) of GABAARs and selec-
tively potentiate or inhibit activity, and in some cases directly gate the channel.
A number of crystal structures of prokaryotic and eukaryotic pLGICs have now
been solved, including the first GABAAR structure, the human b3 homopen-
tamer. However, high resolution structures that reveal the molecular basis
for allosteric modulation of GABAARs are currently unavailable. Here we
report the construction, characterization and crystallization of a chimeric
pLGIC, which is amenable to structural studies of GABAAR transmembrane
pharmacology.
We have generated a chimeric receptor of the extracellular segment from the
proton-gated ion channel from Gloeobacter violaceus (GLIC) and the trans-
membrane segment of the anion-selective human a1 GABAA receptor. The
GLIC-a1 chimera formed functional proton-gated channels when expressed
in Xenopus oocytes. Proton gated currents of the chimeric channel were poten-
tiated by positive modulatory neurosteroids and depressed by inhibitory neuro-
steroids, whilst GLIC is normally insensitive to these compounds. This receptor
can be overexpressed in insect cells and used to generate purified and intact ho-
mopentameric receptor (as determined by native mass spectrometry). Further-
more the purified protein can be used to grow protein crystals under a range of
conditions. We are currently carrying out crystallization trials to generate
diffraction quality crystals of our chimera for structural determinations.
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Dopamine is a critical neuromodulator that governs movement and motivation.
Although dopamine is only thought to target GPCRs in vertebrates (D1-5), it
can activate a Cys-loop pentameric ligand-gated ion channel in C. elegans
(LGC-53). This channel shares homology with mammalian GABAA receptors,
among other Cys-loop channels. The GABAA b3 subunit in particular is impor-
tant for mediating tonic GABA signaling in dopamine-projecting striatal me-
dium spiny neurons. We found 30% residue identity between ligand-binding
domains of LGC-53 and b3, and hypothesized that b3-containing GABAA
receptors may be directly modulated by DA. To address this, we used
immunolabeling with specific anti-b3 antibodies and whole-cell patch clamp
434a Tuesday, February 10, 2015electrophysiology in cultured rat striatal neurons and transfected HEK 293
cells. We determined that 79 53% of cultured cells endogenously expressed
b3, and 94% of neurons gave tonic-level GABA-evoked currents blocked by
phasic concentrations of dopamine (0.1-10 mM). Inhibition was recapitulated
in HEK 293 cells transfected with a1b3, a1b3d or a1b2g2 subunits, but we
instead observed potentiation in a1b3g2 and a5b3g2. Surprisingly, dopamine
(1 mM) evoked rapid currents in a1b2g2, a1b3g2 and a5b3g2 in the absence
of GABA. In a1b3(H267A)g2 (a1Zb3g2) receptors insensitive to trace Zn2þ
inhibition, we found that other biogenic amines evoked comparatively smaller
currents than DA. When the ratio of a1 was increased or we mutated a critical
Zb3 tyrosine residue (Y62L), relative dopamine responses decreased. Further-
more, dopamine activity was retained but GABA activity was drastically
reduced in Zb3g2 receptors, while Zb3 or g2 alone did not elicit currents.
Finally, dopamine currents were picrotoxin- but not bicuculline- or gabazine-
sensitive. Taken together, dopamine at phasic levels is a GABAA allosteric
modulator that may inhibit tonic GABA in prototypical a-containing GABAA
receptors. However, at b/g-containing receptors that do not need a subunits,
dopamine acts as a positive allosteric modulator.
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GABA(A) receptors shape synaptic transmission by modulating Cl- conduc-
tance across the cell membrane. Remarkably, animal toxins that target
GABA(A) receptors have not yet been identified. Here, we report the discovery
of MmTX1 and MmTX2, two toxins present in Costa Rican coral snake venom
that bind to GABA(A) receptors at nanomolar concentrations. Studies with
recombinant and synthetic toxin variants on hippocampal neurons and
cells expressing common receptor compositions suggest that MmTX1 and
MmTX2 potentiate GABA(A) receptor opening and accelerate desensitization
when an agonist is present. In concert, hippocampal neuron excitability
measurements reveal a toxin-induced transitory network inhibition followed
by an increase in spontaneous activity. Moreover, toxin injections into mouse
brain result in reduced basal activity between intense seizures. Altogether, we
characterized the first animal toxins that potently modulate GABA(A) receptor
function, thereby establishing a novel class of tools to study this receptor
family.
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GABA-A receptors (GABAARs) are the target for many therapeutic drugs
including benzodiazepines (BZDs), barbiturates, anesthetics and neurosteroids.
These drugs bind to distinct sites and potentiate GABA-induced currents. They
are often used in combination but little is known about mechanism(s) under-
lying their interactions. Recent crystal structures of GLIC and the glutamate-
activated chloride channel suggest agonist-mediated channel opening is
associated with expansion of transmembrane interfaces between M3 and M1
helices of adjacent subunits. Here, we examined if binding of different allo-
steric drugs and combinations of these drugs to a1b2g2L GABAARs induce
similar motions. We also tested whether potentiation of GABA-mediated cur-
rent by pairs of drugs binding to distinct sites are additive or super-additive.
We individually inserted a cysteine in the M1 helices of each GABAAR subunit
at a1I227, b2L223 and g2LI238 to monitor motions at different intersubunit in-
terfaces. We expressed wild-type and mutant GABAARs in Xenopus oocytes.
We measured rates of modification of the substituted cysteines in the absence
and presence of different combinations of allosteric modulators that bind to
different sites: the intravenous anesthetics pentobarbital (PB) and etomidate,
the neurosteroid THDOC and the benzodiazepine flurazepam. When applied
alone, flurazepam and THDOC induced distinct motions in the intersubunit in-
terfaces, flurazepam increased rate of modification of only gI238C whereas
THDOC only increased the rate of bL223C. When flurazepam and THDOC
were co-applied, no change in rate of modification of gI238C was observed
indicating that the presence of THDOC inhibited the ability of flurazepam toelicit structural rearrangements near gI238C. The data suggest structural mech-
anisms underlying the effects of combining drugs are different than mecha-
nisms underlying their actions alone.
Ion Channel Regulatory Mechanisms II
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The cardiac sodium-calcium exchanger (NCX1) is an important regulator of
intracellular Ca2þ ([Ca2þ]i) and a potential therapeutic target in heart failure.
Among potential interacting partners regulating NCX1 activity is the trans-
membrane protein phospholemman (PLM); a substrate for protein kinase A
and protein kinase C. Several reports have demonstrated that binding of phos-
phorylated PLM (pSer68-PLM) to NCX1 leads to NCX1 inhibition, while other
studies have failed to demonstrate a functional interaction of these proteins. In
present study, we aimed to analyze the biological function of the pSer68-PLM-
NCX1 interaction by developing anchoring disruptor peptides. We observed
that PLM co-fractionated and co-immunoprecipitated with NCX1 in rat left
ventricle (LV) and in co-transfected HEK293 cells. Strong binding of
pSer68-PLM to one of the previously reported NCX1-QKHPD regions was
demonstrated in pull-down and overlay assays. Single amino acid substitutions
of native NCX1 peptide sequence 1-KHPDKEIEQLIELANYQVLS-20 re-
vealed that single substitutions at position 1-11 (particularly with tryptophan
or tyrosine) increased binding affinity of the peptide to pSer68-PLM. Interest-
ingly, we found that double substitution at position 4 and 6 with tyrosine (D4Y
and E6Y) in the native peptide sequence enhanced the binding affinity to
pSer68-PLM 8-fold, compared to native sequence. The optimized peptide 1-
KHPYKYIEQLIELANYQVLS-20 was further tested in a series of electro-
physiological experiments using whole-cell voltage clamp technique, with
voltage-ramp protocol employed to elicit NCX current. Constitutively phos-
phorylated (S68D) PLM was observed to inhibit NCX1 current in both forward
and reverse mode. Inclusion of the disruptor peptide in the patch pipette
reversed S68D-PLM inhibition of NCX1, while NCX current was not altered
by a scrambled peptide control. Taken together these data strongly suggest
that PLM interacts directly with NCX1, and that when PLM is phosphorylated
at serine 68, the interaction inhibits NCX1 activity.
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Human beta-cell insulin secretion is dependent on Ca2þ entry through voltage-
dependent Ca2þ channels (VDCCs). Kþ channels modulate the beta-cell
membrane potential, which influences VDCC activity. The most abundant
Kþ channel of the human islet is the two-pore domain Kþ (K2P) channel
TALK-1; however, its function is unknown. We characterized TALK-1 cur-
rents in primary mouse beta-cells and find that K2P currents are significantly
reduced after genetic ablation of TALK-1. To identify mechanisms that regu-
late TALK-1 channel activity, we used a Tlþ-sensitive fluorescent screen to
assess if TALK-1 is regulated by kinases. Cells expressing TALK-1 channels
were monitored for changes in Tlþ flux in response to co-expression with a
constitutively active kinase (examining a total of 192 kinases), revealing 9 ki-
nases that modify Tlþ flux through TALK-1. Interestingly, three phosphatidy-
linositol phosphate kinases (PIKs) including PIK3CG, PI4K2B, and PIKFYVE,
increased TALK-1 channel activity. To determine if activation of TALK-1
channels by PIKs is due to build-up of PIPs, we depleted membrane PIP2
with a rapamycin-recruitable phosphatase and found that TALK-1 channel
activity was reduced. As charged residues of other Kþ channels mediate
PIP2 sensitivity, we assessed if PIP2 influences TALK-1 channel activity
through a charged residue enriched domain in the C-terminus. We found that
neutralization of these charged residues significantly reduced PIP2 activation
of TALK-1 channels. Importantly, PIP2 introduced via patch pipette into pri-
mary mouse beta-cells also significantly enhanced TALK-1 currents. As
glucose induces Ca2þ-dependent oscillations in beta-cell PIP2, we then as-
sessed how TALK-1 regulates islet Ca2þ dynamics. We find that Ca2þ oscilla-
tion frequency is significantly increased in islets lacking TALK-1, which
